Baseline characteristics
| COR N=84 | SR N=65 | CR N=65 | p Value | |
| Age, years | 66.5±13.2 | 64.1±11.1 | 64.5±11.7 | 0.413 |
| Male gender | 64 (76.2%) | 52 (80.0%) | 50 (76.9%) | 0.849 |
| Diabetes mellitus | 20 (23.8%) | 12 (18.5%) | 9 (13.8%) | 0.305 |
| Hypertension | 50 (59.5%) | 42 (64.6%) | 32 (49.2%) | 0.192 |
| LVEF before PCI, % | 44.6±10.1 | 45.9±8.6 | 45.4±10.4 | 0.718 |
| LVEF at discharge, % | 45.4±10.3 | 47.2±8.3 | 46.1±9.9 | 0.673 |
| Mass CK-MB peak, ng/ml | 143.1±103.8 | 150.8±92.2 | 155.9±97.6 | 0.853 |
| Systolic blood pressure before PCI, mm Hg | 136.2±30.2 | 136.2±31.4 | 136.0±24.3 | 0.999 |
| Anterior location of STEMI | 35 (41.7%) | 28 (43.8%) | 31 (47.7%) | 0.761 |
| Killip class at admission | 1.48±0.61 | 1.40±0.70 | 1.24±0.53 | 0.083 |
| Three-vessel disease | 21 (25.0%) | 29 (44.6%) | 19 (29.2%) | 0.033 |
| TIMI flow grade before PCI | 0.76±1.21 | 0.89±1.21 | 1.11±1.32 | 0.244 |
| Door-to-balloon time, minutes | 63.1±27.2 | 65.7±19.4 | 60.1±22.6 | 0.824 |
| Drug-eluting stent | 10 (11.9%) | 6 (9.2%) | 5 (7.7%) | 0.722 |
| Chronic renal failure | 24 (29.3%) | 16 (24.6%) | 17 (26.6%) | 0.816 |
| Plasma creatinine before PCI, mg/dl | 1.14±0.69 | 1.13±0.99 | 0.98±0.27 | 0.369 |
| CIN | 3 (3.6%) | 2 (3.1%) | 1 (1.5%) | 0.748 |
| Length of hospital stay, days | 5.3±2.5 | 5.4±3.1 | 4.8±2.6 | 0.348 |
| Therapy at discharge | N=77 | N=65 | N=63 | |
| Aspirin | 74 (96.1%) | 65 (100%) | 62 (98.4%) | 0.239 |
| Clopidogrel | 71 (92.2%) | 65 (100%) | 61 (96.8%) | 0.054 |
| Beta-blockers | 62 (80.5.7%) | 52 (80.0%) | 52 (82.5%) | 0.927 |
| Statins | 68 (88.3%) | 60 (92.3%) | 57 (90.5%) | 0.724 |
| Nitrates | 16 (20.8%) | 4 (6.2%) | 4 (6.3%) | 0.007 |
| ACE inhibitors | 48 (62.3%) | 38 (58.5%) | 35 (55.6%) | 0.594 |
ACE, angiotensin-converting enzyme; CIN, contrast-induced nephropathy; CK-MB, MB isoenzyme of creatine kinase; COR, culprit-only revascularisation; CR, complete revascularisation; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SR, staged revascularisation; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.9